Series Seed Round
Join us in transforming interventional pulmonology through AI-guided robotics and optical sensing
The Problem
Critical gaps in lung cancer diagnosis
Our Solution
Naviscope: AI-Guided Navigation Platform
Market Opportunity
Projected to reach $17.6B by 2030
Progress & Validation
Major milestones achieved
Use of Funds – $1.5M Seed Round
Clinical Development
40%30-patient first-in-human pilot study
Regulatory Pathway
25%FDA 510(k) preparation and submission
Product Development
25%Design optimization, manufacturing scale-up
Team Expansion
10%Key clinical and engineering hires
18-Month Milestones
Our Team
Leadership Team
Limor Prigan
CEO
Ex-Fujifilm, Avertto, Kornit
Yaniv Kirma
CTO
Co-founder, Fibernova (acquired by Broncus)
Prof. Doron Kopelman
CMO
Technion / Israeli Surgical Association
Dan Vigdor
Global Business Development (USA)
International commercialization expert
Medical Advisory Board
- Prof. Eli Atar
- Prof. Moti Kramer
- Prof. Doron Kopelman
Why It Matters
Naviscope is the first step toward a future of AI-guided, radiation-free navigation in interventional pulmonology. By integrating AI, robotics, and optical sensing, LumenGuides aims to drastically improve how clinicians detect and treat early-stage lung cancer—potentially saving thousands of lives each year.